Carvolix SA (EPA:CVX)

France · Delayed Price · Currency is EUR

4.850

-0.090 (-1.82%)

Nov 13, 2026, 5:35 PM CET

Market Cap	301.81M +377.9%
Revenue (ttm)	1.59M -69.8%
Net Income	-29.48M
EPS	-0.62
Shares Out	62.23M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,558
Open	5.100
Previous Close	4.940
Day's Range	4.850 - 5.100
52-Week Range	1.330 - 7.560
Beta	1.17
Analysts	Buy
Price Target	8.78 (+80.93%)
Est. Earnings	Dec 24, 2026

About Carvolix

Carvolix SA, a medical technology company, develops and markets minimally invasive, minimally invasive medical devices in the field of urology and structural heart in France. It offers Artus, an implantable electro-mechanical artificial sphincter that targets moderate to severe urinary incontinence; and Kalios and Epygon implants for the treatment of mitral insufficiency, as well as Kardiozis technology for treating abdominal aortic aneurysm. The company also offers TAVIPILOT Software, a robotic platform for transcatheter aortic valve implantat... [Read more]

Industry Medical Devices

Sector Healthcare

Founded 2011

Employees 102

Stock Exchange Euronext Paris

Ticker Symbol CVX

Full Company Profile

Financial Performance

In 2025, Carvolix's revenue was 900,000, a decrease of -83.18% compared to the previous year's 5.35 million. Losses were -24.97 million, 69.4% more than in 2024.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for CVX stock is "Buy." The 12-month stock price target is €8.78, which is an increase of 80.93% from the latest price.

Price Target

€8.78

(80.93% upside)

Analyst Consensus: Buy

Stock Forecasts